Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study.

ABSTRACT:

Background

Interstitial lung disease (ILD) encompasses a heterogeneous group of disorders sharing pathophysiological inflammatory mechanisms, leading to parenchymal distortions. The prevalence of ILD with new cancer drugs is underreported: the identification of potential determinants is priority.

Materials and methods

ILDE is a retrospective study aimed at describing the clinical course and potential determinants of ILD in patients receiving experimental treatments.

Results

We identified 226 eligible patients, of whom 5.3% (n = 12) had ILD. In five patients, the diagnosis was radiological, while seven patients had initial cough, dyspnea, fatigue or fever. ILD was graded as grade 1 (G1) in four, G2 in five and G3 in three patients. The first occurrence of ILD resolved

SUBMITTER: Trapani D 

PROVIDER: S-EPMC11345526 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature